August 26, 2026 12:00 pm
LVBCH OBESITY LEARNING COLLABORATIVE
EMPLOYER MEMBERS ONLY
About the Obesity Learning Collaborative: The obesity learning collaborative is an ongoing peer-to-peer discussion and educational series featuring local employers and clinical experts on obesity topics. For the past three years, these sessions have focused on comprehensive obesity care while also taking a deeper dive into the landscape around GLP-1s and other anti-obesity medications.
This Obesity Learning Collaborative welcomes Laura Rissover and Katie Wubbenhorst of Aon, who will share learnings from Aon’s “Workforce-Focused Analysis on GLP1s” report.
Beyond the Headlines: What Aon's Real-World GLP-1 Research Means for Employers
Aon’s latest analysis of GLP-1 users provides new insights into medical cost trends, adherence, women’s health outcomes, cancer, and emerging clinical impacts across a nationally representative commercial population. Join us as we explore what these findings mean for employers developing long-term obesity, chronic disease, and workforce health strategies.
Learning Objectives
By attending this presentation, participants will be able to:
- Describe key findings from Aon’s Phase II GLP-1 research, including impacts on medical cost trends, healthcare utilization, and adherence.
- Evaluate emerging evidence related to GLP-1 therapies across cancer, cardiovascular health, women’s health, and other evolving clinical outcomes.
- Assess how adherence influences both health outcomes and the long-term value of GLP-1 therapy.
- Identify strategic considerations and benefit design approaches employers can use when developing obesity and weight management programs.
Laura Rissover
Laura Rissover is a Vice President of Health Analytics in Aon’s Human Capital organization where she leads health-focused analytic engagements on Total Rewards, Women’s Health, and Pharmacy, and provides Health Solutions thought leadership on workforce-focused GLP-1 analytics.
Laura joined Aon in 2025, bringing more than 30 years of Health Analytics leadership to the firm and its clients. Prior to joining Aon, Laura spent a decade at the Blue Cross Blue Shield Association where she led Health Economics and Outcomes Research (HEOR) initiatives, population health programs, and analytic engagements on innovation, disruptive technologies, and value-based care. Laura has also held leadership positions at Merative, IQVIA, and Abbott Laboratories.
Laura draws upon her experience in healthcare consulting, pharmacy, and payer / employer dynamics, to develop data-driven insights to aid employers in making decisions that align with organizational goals and improve workforce health outcomes.
Katie Wubbenhorst, PharmD
Katie Wubbenhorst is a Vice President of Pharmacy Consulting at Aon, where she focuses on building relationships and helping complex employers, hospitals and health systems, and health plans make better decisions in managing pharmacy spend and trend. Her work at Aon includes ongoing pharmacy consulting, custom formulary evaluations, PBM RFPs, market checks, PBM renewals, contract negotiation, and custom project work as needed.
In addition to her client responsibilities, Katie serves as Aon’s Northeast Regional Pharmacy Leader, helping drive pharmacy strategy, talent development, and practice growth across the region. She also serves as a Clinical Thought Leader for the pharmacy practice, providing strategic insight on emerging market trends, clinical innovation, pharmacy benefit management, specialty pharmacy, GLP-1 strategies, and evolving healthcare regulations.
Katie utilizes her retail and clinical experience to consult on a wide range of pharmacy benefit strategies while balancing financial performance, clinical outcomes, and the member experience.
Katie utilizes her retail and clinical experience to consult on a wide range of pharmacy benefit strategies while keeping in mind clinical outcomes and the member experience.
Katie holds a Doctor of Pharmacy degree from the University of the Sciences.
Mark Napier, MD, FCCP
Dr. Mark Napier is Aon’s Chief Medical Officer for North America. Prior to joining Aon, Dr. Napier spent that last decade working for a carrier providing strategic clinical support to national accounts clients. Dr. Napier is board certified in pulmonary and critical care medicine and he helped found and served as medical director for a multi-disciplinary lung cancer program while in clinical practice. He has maintained a deep interest in cancer prevention, early detection, and optimal cancer treatment. He provides clinical leadership on complex, high-cost conditions: especially obesity / cardiometabolic risk, cancer, gene therapy and the practical realities of coverage, cost, and medical–pharmacy integration. During the first surge in COVID cases in New York, Dr. Napier returned to working in the intensive care unit on weekends.
Dr. Napier graduated from Boston University School of Medicine in 2000. He completed a residency in internal medicine at Boston Medical Center, followed by a fellowship in pulmonary and critical care medicine at Maine Medical Center in Portland, Maine. Dr. Napier was an attending physician and assistant professor of medicine at Albany Medical College, in Albany, New York.
PRESENTING SPONSOR
